List of Stivarga drug patents

Stivarga is owned by Bayer Hlthcare.

Stivarga contains Regorafenib.

Stivarga has a total of 5 drug patents out of which 1 drug patent has expired.

Expired drug patents of Stivarga are:

  • US7351834

Stivarga was authorised for market use on 27 September, 2012.

Stivarga is available in tablet;oral dosage forms.

Stivarga can be used as treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor.

The generics of Stivarga are possible to be released after 09 July, 2032.

STIVARGA's oppositions filed in EPO
STIVARGA Litigations
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7351834 BAYER HLTHCARE ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Jun, 2022

(8 months ago)

US8637553 BAYER HLTHCARE Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
Feb, 2031

(7 years from now)

US9957232 BAYER HLTHCARE 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate
Jul, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8680124 BAYER HLTHCARE Treatment of cancers with acquired resistance to kit inhibitors
Jun, 2030

(7 years from now)

US9458107 BAYER HLTHCARE Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorphenoxy-N-ethylpyridie-carboxamide, its salts and monohydrate
Apr, 2031

(8 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Apr 27, 2024

Drugs and Companies using REGORAFENIB ingredient

Market Authorisation Date: 27 September, 2012

Treatment: Treatment of patients with gastrointestinal stromal tumor (gist), including but not limited to patients previously treated with imatinib and patients with gist having resistance to a kit tyrosine kinase inhibitor

Dosage: TABLET;ORAL

How can I launch a generic of STIVARGA before it's patent expiration?
More Information on Dosage

STIVARGA family patents

23

United States

11

European Union

6

Argentina

6

China

6

Japan

6

Australia

5

Brazil

5

Korea, Republic of

5

Canada

4

Malaysia

4

Spain

4

Costa Rica

4

New Zealand

4

Taiwan, Province of China

4

Hong Kong

4

Israel

3

Portugal

3

Singapore

3

Uruguay

3

Russia

3

Guatemala

3

Mexico

3

Morocco

3

Peru

3

Tunisia

3

Slovenia

3

Ukraine

3

Poland

3

Chile

3

Denmark

2

Jordan

2

Croatia

2

Colombia

2

Dominican Republic

2

Honduras

2

South Africa

2

Cyprus

2

Hungary

2

Cuba

2

Ecuador

1

Germany

1

El Salvador

1

Panama

1

Norway

1

EA

1

Luxembourg

1

ME

1

Yugoslavia

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic